DOP2019000156A - Fenitoina topica para uso en el tratamiento del dolor neuropático periférico - Google Patents

Fenitoina topica para uso en el tratamiento del dolor neuropático periférico

Info

Publication number
DOP2019000156A
DOP2019000156A DO2019000156A DO2019000156A DOP2019000156A DO P2019000156 A DOP2019000156 A DO P2019000156A DO 2019000156 A DO2019000156 A DO 2019000156A DO 2019000156 A DO2019000156 A DO 2019000156A DO P2019000156 A DOP2019000156 A DO P2019000156A
Authority
DO
Dominican Republic
Prior art keywords
neuropathic pain
topical
peripheral neuropathic
phenytoin
neuropathies
Prior art date
Application number
DO2019000156A
Other languages
English (en)
Inventor
Marius Keppel Hesselink Jan
Jos Kopsky David
Original Assignee
Topical Innovations B V
Marius Keppel Hesselink Jan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topical Innovations B V, Marius Keppel Hesselink Jan filed Critical Topical Innovations B V
Publication of DOP2019000156A publication Critical patent/DOP2019000156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que contienen fenitoína o fenitoína sódica para uso en el alivio del dolor tópico. Dicho uso de la composición farmacéutica de la invención reduce el dolor neuropático periférico. tópico ­ Las composiciones farmacéuticas de la invención que contienen fenitoína o fenitoína sódica, sorprendentemente reducen el dolor neuropático periférico considerablemente, especialmente y preferiblemente en las condiciones, caracterizadas por un grado bajo a moderado de inflamación neurogénica periférica. ­ Según la invención, tales como neuropatía de fibra pequeña, neuropatía diabética, polineuropatía axonal idiopática crónica, neuralgia posherpética, neuralgia del trigémino, polineuropatía inducida por quimioterapia, neuropatías traumáticas, neuropatías por compresión y neuropatías infecciosas en remisión, según la invención.
DO2019000156A 2016-12-06 2019-06-06 Fenitoina topica para uso en el tratamiento del dolor neuropático periférico DOP2019000156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2017931 2016-12-06
PCT/NL2017/050814 WO2018106107A1 (en) 2016-12-06 2017-12-06 Topical phenytoin for use in the treatment of peripheral neuropathic pain

Publications (1)

Publication Number Publication Date
DOP2019000156A true DOP2019000156A (es) 2020-07-15

Family

ID=57796933

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000156A DOP2019000156A (es) 2016-12-06 2019-06-06 Fenitoina topica para uso en el tratamiento del dolor neuropático periférico

Country Status (17)

Country Link
US (1) US11285099B2 (es)
EP (1) EP3551166A1 (es)
JP (1) JP7264813B2 (es)
CN (1) CN110248644A (es)
AU (1) AU2017371467B2 (es)
BR (1) BR112019011743A2 (es)
CA (1) CA3046055A1 (es)
CL (1) CL2019001550A1 (es)
DO (1) DOP2019000156A (es)
EA (1) EA201991341A1 (es)
IL (1) IL267114B1 (es)
MA (1) MA51978A (es)
MX (1) MX2019006640A (es)
PH (1) PH12019550093A1 (es)
UA (1) UA125040C2 (es)
WO (1) WO2018106107A1 (es)
ZA (1) ZA201906473B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005034B2 (en) 2017-04-25 2024-06-11 Algotherapeutix Topical pharmaceutical composition comprising at least amitriptyline, for the treatment of peripheral neuropathic pain
US20220313649A1 (en) 2019-09-02 2022-10-06 Syddansk Universitet P-gp inducers as protectors against chemotherapy-induced side effects, such as peripheral neuropathy (cipn) and hair loss
CN114681340A (zh) * 2022-04-13 2022-07-01 肌赋萃生物科技(上海)有限公司 一种含有脂质包裹稳定技术的脂质屏障修复护肤品及其制备方法
WO2024120461A1 (zh) * 2022-12-09 2024-06-13 荣昌生物制药(烟台)股份有限公司 Cyp3a4/5诱导剂在治疗或缓解周围神经病变中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571521A (en) 1984-01-16 1996-11-05 Lasker; Sigmund E. Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition
JPH0772190B2 (ja) * 1985-02-26 1995-08-02 エーザイ株式会社 ヒダントイン誘導体
JP3031973B2 (ja) 1990-08-16 2000-04-10 富士レビオ株式会社 フェニトイン誘導体
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
CN1046199C (zh) * 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
AU4078897A (en) 1996-08-23 1998-03-06 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
WO2001000191A2 (en) * 1999-06-23 2001-01-04 Warner-Lambert Company Use of fosphenytion for the treatment of acute neuropathic pain
US20040191276A1 (en) 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
JP2004531548A (ja) 2001-05-15 2004-10-14 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ナトリウムフェニトイン剤形の製造のための圧縮方法
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
AU2005268929A1 (en) 2004-08-03 2006-02-09 Royal College Of Surgeons In Ireland Phenytoin formulations, and uses thereof in wound healing
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
CN101069692B (zh) * 2006-05-08 2011-04-20 范敏华 含积雪草总甙的药物制剂及其制备方法
WO2008079727A2 (en) 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
EP2286828B1 (en) * 2008-04-14 2016-05-18 National University Corporation Nagoya University Improving agent for neuropathic pain
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ，エルエルシー 局所局部的神経作用療法
AU2009296457A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
KR101271219B1 (ko) * 2011-01-27 2013-06-07 광주과학기술원 신규한 하이단토인 유도체 및 이의 용도
ES2759582T3 (es) 2011-06-20 2020-05-11 Hisamitsu Pharmaceutical Co Parche que contiene lidocaína
US20130184351A1 (en) 2011-12-21 2013-07-18 Jar Laboratories Lidocaine patch and methods of use thereof
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
WO2015089050A1 (en) * 2013-12-09 2015-06-18 Malshe Research And Development, Llc Compositions and methods for the treatment of wounds
CN106075556A (zh) * 2016-06-02 2016-11-09 四川奎星医用高分子制品有限责任公司 含有促进伤口愈合药物的医用复合壳聚糖凝胶

Also Published As

Publication number Publication date
IL267114B1 (en) 2024-04-01
MA51978A (fr) 2021-01-20
JP7264813B2 (ja) 2023-04-25
US20200276106A1 (en) 2020-09-03
BR112019011743A2 (pt) 2019-10-22
PH12019550093A1 (en) 2020-02-10
MX2019006640A (es) 2019-08-01
WO2018106107A1 (en) 2018-06-14
AU2017371467B2 (en) 2023-06-01
EA201991341A1 (ru) 2019-12-30
ZA201906473B (en) 2020-07-29
CL2019001550A1 (es) 2020-02-28
AU2017371467A1 (en) 2019-07-25
EP3551166A1 (en) 2019-10-16
JP2020500915A (ja) 2020-01-16
IL267114A (en) 2019-08-29
UA125040C2 (uk) 2021-12-29
CN110248644A (zh) 2019-09-17
US11285099B2 (en) 2022-03-29
CA3046055A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
DOP2019000156A (es) Fenitoina topica para uso en el tratamiento del dolor neuropático periférico
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CU20130033A7 (es) Imidazopiridazinas sustituidas
UY34053A (es) FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CR20150455A (es) Imidazopiridazinas sustituidas
CO6511249A2 (es) Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2021003142A1 (es) Inhibidores de pequeñas moléculas de la cinasa inductora del nf-kb.
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
UY37577A (es) Dihidroimidazopiridindionas sustituidas
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112014031706A8 (pt) Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
ECSP13012460A (es) 2-oxo- y 2-tioxo-dihidroquinolina-3-carboxamidas sustituidos como moduladores KCNQ2/3
ECSP15037180A (es) Extracto de café que contiene ácido protocatecuico y su uso en agroquímica contra patógenos de plantas
CO2019010663A2 (es) Composición de carbohidratos para la diálisis
CL2022003426A1 (es) Composición farmacéutica acuosa de levilimab y su uso
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor